Eli Lilly Announced Sunday At ESMO, Olomorasib Plus Chemoimmunotherapy Data Showing 62% Overall Response Rate, 14.5-Month Median Response Duration In First-Line KRAS G12C NSCLC

뉴스 본문을 불러오고 있어요.

Eli Lilly Announced Sunday At ESMO, Olomorasib Plus Chemoimmunotherapy Data Showing 62% Overall Response Rate, 14.5-Month Median Response Duration In First-Line KRAS G12C NSCLC | 웨이프 WAPE

Eli Lilly Announced Sunday At ESMO, Olomorasib Plus Chemoimmunotherapy Data Showing 62% Overall Response Rate, 14.5-Month Median Response Duration In First-Line KRAS G12C NSCLC

기사 요약

관련 종목

댓글 —